AFT Pharmaceuticals (ASX:AFP, NZE:AFT) maintained its fiscal 2026 operating profit in the range of NZ$20 million to NZ$24 million and said it is on track to meet fiscal 2027 revenue of NZ$300 million, according to a Thursday filing with the New Zealand bourse.
The company is developing eight patented products and progressing 24 off-patent injectables, the filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。